Sugi Predict

Sugi Predict / Targets / SLC1A3

SLC1A3

Excitatory amino acid transporter 1 · P43003 · SLC1A3 on Sugi Atlas →

70,972 patent compounds predicted against SLC1A3, 41,018 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL46226 SCHEMBL46226 0.51 8/20
SCHEMBL46577 SCHEMBL46577 0.88 6/20
Leucine Leucine (SCHEMBL175940) 0.74 6/20
Leucine Leucine (SCHEMBL175941) 0.74 6/20
SCHEMBL46561 SCHEMBL46561 0.74 6/20
Leucine Leucine (SCHEMBL67322) 0.71 6/20
SCHEMBL46217 SCHEMBL46217 0.69 6/20
Leucine Leucine (SCHEMBL165422) 0.57 6/20
Leucine Leucine (SCHEMBL122270) 0.55 6/20
Leucine Leucine (SCHEMBL122271) 0.55 6/20
Aspartic Acid Aspartic Acid (SCHEMBL135731) 0.52 6/20
Leucine Leucine (SCHEMBL138874) 0.50 6/20
Valine Valine (SCHEMBL111113) 0.38 6/20
SCHEMBL30895 SCHEMBL30895 1.00 5/20
SCHEMBL71719 SCHEMBL71719 1.00 5/20
SCHEMBL46552 SCHEMBL46552 0.74 5/20
Glutamic Acid Glutamic Acid (SCHEMBL24357) 0.72 5/20
SCHEMBL46558 SCHEMBL46558 0.70 5/20
SCHEMBL136824 SCHEMBL136824 0.70 5/20
SCHEMBL46467 SCHEMBL46467 0.66 5/20

Clinical trials — most relevant to SLC1A3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Pilot Study: Postoperative Pain Reduction by Pre Emptive N-Acetylcysteine PHASE4COMPLETED
Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD PHASE3COMPLETED
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia PHASE1/PHASE2RECRUITING
Ketamine Infusion for Obsessive-Compulsive Disorder PHASE2COMPLETED
Therapeutic Efficacy of L-Ornithine L-Aspartate Infusion in Patients With Acute Liver Failure PHASE2UNKNOWN
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia PHASE2COMPLETED
A Glutamate Transporter GLT1, in the Treatment of Bipolar Disorder PHASE2WITHDRAWN
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders PHASE2COMPLETED
Study on Amino Acid Uptake in Brain Tumors PHASE2UNKNOWN
DAAOI-1 Treatment for Treatment-resistant Schizophrenia PHASE2COMPLETED
D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia PHASE2COMPLETED
Placebo-Controlled Trial With GlyTI-M Among Children With Attention Deficit Hyperactivity Disorder (ADHD) PHASE2COMPLETED
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia PHASE1COMPLETED
Excitatory Amino Acids and Activated Microglia After Traumatic Brain Injury: a (R)-[11C]PK11195 PET Study PHASE1UNKNOWN
Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy EARLY_PHASE1ACTIVE_NOT_RECRUITING
D-aspartate and Therapeutic Exercise EARLY_PHASE1UNKNOWN
CRF vs WCRF or PRF-DRG in CLBP of FJ Origin and RFA Failure of MBDR: Central Sensitization and Aberrant Nerve Sprouting nanUNKNOWN
A Study of Cases with Abnormal Serum Ammonia in Neonate and Children Attending Assiut University Children Hospital nanNOT_YET_RECRUITING
SLC13A5 Deficiency Natural History Study - United States Only nanENROLLING_BY_INVITATION
[18F] FDOPA PET Imaging in Glioma: Feasibility Study for PET Guided Brain Biopsy nanUNKNOWN
High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions nanCOMPLETED
Stem Cell Study of Genetics and Drug Addiction nanCOMPLETED
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy nanCOMPLETED
Development of A Technique to Predict Antidepressant Responsiveness in Depressive Patients nanUNKNOWN
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs nanCOMPLETED
Pharmacogenetic and Neurofunctional Brain Areas Study in Obese Patients With Binge Eating Disorder nanUNKNOWN
Establishing the Salience of Type 1 Interferon Pathway Blockade in the Central Mechanisms of SLE Related Fatigue nanNOT_YET_RECRUITING
Effects of Sulfasalazine on BOLD Response to Alcohol Cues nanCOMPLETED
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy) nanUNKNOWN
sCD163 in ALS Patients nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC1A3 binder may also engage these)

ProteinNameSimilarity
P46411 — 1.000 P46411 →
P24942 — 1.000 P24942 →
P56564 — 1.000 P56564 →
O57321 — 1.000 O57321 →
P31597 — 0.996 P31597 →
P51907 — 0.995 P51907 →
SLC1A1 Excitatory amino acid transporter 3 0.993 landscape →
P51906 — 0.990 P51906 →
Q95135 — 0.988 Q95135 →
P43006 — 0.986 P43006 →
P31596 — 0.985 P31596 →
O00341 — 0.985 O00341 →
SLC1A2 Excitatory amino acid transporter 2 0.984 landscape →
Q8JZR4 — 0.983 Q8JZR4 →
Q25605 — 0.981 Q25605 →
O35544 — 0.980 O35544 →
Q10901 — 0.979 Q10901 →
O35921 — 0.979 O35921 →
O35874 — 0.978 O35874 →
Q9N1R2 — 0.975 Q9N1R2 →
P48664 — 0.974 P48664 →
A2VDL4 — 0.969 A2VDL4 →
P51912 — 0.966 P51912 →
P55014 — 0.966 P55014 →
Q95JC7 — 0.964 Q95JC7 →
P43007 — 0.964 P43007 →
Q4R8W8 — 0.963 Q4R8W8 →
P55016 — 0.962 P55016 →
P55015 — 0.962 P55015 →
Q21353 — 0.962 Q21353 →